PLN 92.8
(-1.28%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 5.96 Million PLN | 61.47% |
2022 | 3.69 Million PLN | 67.63% |
2021 | 2.2 Million PLN | 114.85% |
2020 | 1.02 Million PLN | 206.9% |
2019 | 334.37 Thousand PLN | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 2.19 Million PLN | 59.12% |
2024 Q2 | 550 Thousand PLN | -73.81% |
2023 Q4 | 1.38 Million PLN | -8.23% |
2023 Q1 | 1.41 Million PLN | 39.56% |
2023 Q2 | 1.66 Million PLN | 18.21% |
2023 Q3 | 1.5 Million PLN | -9.71% |
2023 FY | 7 Million PLN | 89.45% |
2022 Q1 | 878.82 Thousand PLN | 26.3% |
2022 FY | 3.69 Million PLN | 67.63% |
2022 Q4 | 1.01 Million PLN | 45.68% |
2022 Q3 | 694 Thousand PLN | -32.62% |
2022 Q2 | 1.03 Million PLN | 17.2% |
2021 Q4 | 695.79 Thousand PLN | 13.32% |
2021 Q3 | 614 Thousand PLN | 74.74% |
2021 Q2 | 351.37 Thousand PLN | -35.37% |
2021 Q1 | 543.7 Thousand PLN | 0.0% |
2021 FY | 2.2 Million PLN | 114.85% |
2020 Q2 | 203.11 Thousand PLN | 0.0% |
2020 FY | 1.02 Million PLN | 206.9% |
2019 FY | 334.37 Thousand PLN | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bioceltix S.A. | 15.38 Million PLN | 61.208% |
BIOTON S.A. | 57.55 Million PLN | 89.631% |
Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 92.532% |
Mabion S.A. | 59.52 Million PLN | 89.973% |
Molecure S.A. | 31.73 Million PLN | 81.192% |
NanoGroup S.A. | 7.82 Million PLN | 23.748% |
Pharmena S.A. | -32.76 Million PLN | 118.215% |
Poltreg S.A. | 15.47 Million PLN | 61.435% |
Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 79.522% |
Ryvu Therapeutics S.A. | 4.73 Million PLN | -25.96% |
Synthaverse S.A. | 26.35 Million PLN | 77.354% |